Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial

Fig. 1

Study design and clinical outcomes of SHR-1701 plus famitinib in advanced BTC and PDAC. a Upper: Schematic representation of the bifunctional fusion protein SHR-1701. Lower: Treatment schedule of (1) SHR-1701 and (2) famitinib in the study. Q3w, every three weeks; i.v., intravenously; p.o., orally. b CONSORT (Consolidated Standards of Reporting Trials) diagram of patient disposition in the biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC) cohorts. Six patients were not evaluable for tumor response due to an early death (n = 3) or withdrawal of consent (n = 3) before the first scheduled post-baseline imaging assessment. c Waterfall plot of the best percent change from baseline in target lesion size and the best response for evaluable patients in the BTC and PDAC cohorts. *, tumor growth < 5 mm, still classified as stable disease per RECIST criteria. d Kaplan-Meier curve of progression-free survival (PFS) for the BTC cohort. Median PFS: 5.1 months (95% CI, 2.6–7.6). CI, confidence interval. e Kaplan-Meier curve of PFS for the PDAC cohort. Median PFS: 2.1 months (95% CI, 0.7-3.5). f Kaplan-Meier curve of overall survival (OS) for the BTC cohort. Median OS: 16.0 months (95% CI, 6.1-NE). NE, not estimable. g Kaplan-Meier curve of OS for the PDAC cohort. Median OS: 5.3 months (95% CI, 4.0–6.5)

Back to article page